A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

Key Inclusion Criteria: * Adults, ≥ 18 years of age at the time of signing the informed consent * Participants who are medically stable such that, according to the judgement of the Investigator, hospitalization within the study period is not anticipated and the participant appears likely to be able to remain on study through the end of protocol-specified follow-up. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months prior to enrollment * Written informed consent and any locally required authorization (eg, HIPAA in the US) obtained from the participant prior to performing any protocol-related procedures, including screening evaluations Key Exclusion Criteria: * History of hypersensitivity to any component of the IMP * History of hypersensitivity to penicillin and its derivatives * History of severe adverse reaction and/or severe allergic reaction (eg, anaphylaxis associated with a vaccine * Known or suspected congenital or acquired immunodeficiency * Abnormal findings on screening laboratory tests * Previous history of myocarditis, pericarditis, Guillain-Barré syndrome or any other demyelinating condition * Known or suspected autoimmune conditions as determined by history and/or physical examination * Receipt of any other type of seasonal influenza vaccination from 14 days before the first dose until 28 days after the administration of the last dose of IMP * Receipt of an m…